CardioVascular BioTherapeutics (CVBT) announced data from its Phase 2 studies of CVBT-141B for the treatment of diabetic wounds. Results from the two randomized, double-blind, placebo-controlled Phase 2a and 2b trials showed that diabetic wounds treated with CVBT-141B healed approximately 4.5 times faster than wounds treated with placebo/standard of care. The studies also showed that diabetic wounds achieved 100% closure within five months or less, whereas one-third of the placebo-treated wounds remained open at the end of the same treatment period. Additionally, 57% of patients treated with CVBT-141B had complete closure of their diabetic wounds at eight weeks, versus 0% for the placebo group. Both trials demonstrated statistical significance compared with placebo (p<0.05).

CVBT-141B contains the active ingredient fibroblast growth factor-1 (FGF-1), a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.

For more information call (702) 839-7200 or visit